

# Mukund S Chorghade

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11223602/publications.pdf>

Version: 2024-02-01

23  
papers

406  
citations

759233

12  
h-index

752698

20  
g-index

28  
all docs

28  
docs citations

28  
times ranked

449  
citing authors

#	ARTICLE	IF	CITATIONS
1	Protecting group directed ring-closing metathesis (RCM): the first total synthesis of an anti-malarial nonenolide. <i>Tetrahedron Letters</i> , 2007, 48, 2621-2625.	1.4	61
2	Chiral Glycolate Equivalents for the Asymmetric Synthesis of $\hat{1}\pm$ -Hydroxycarbonyl Compounds. <i>Bulletin of the Chemical Society of Japan</i> , 2007, 80, 1451-1472.	3.2	39
3	Synthesis of the spiro fused $\hat{1}^2$ -lactone- $\hat{1}^3$ -lactam segment of oxazolomycin. <i>Tetrahedron Letters</i> , 2006, 47, 6031-6035.	1.4	35
4	Catalytic FeCl <sub>3</sub> - or Yb(OTf) <sub>3</sub> -mediated synthesis of substituted tetrahydrofurans and C -aryl glycosides from 1,4-diols. <i>Tetrahedron: Asymmetry</i> , 2002, 13, 687-690.	1.8	30
5	A novel and simple asymmetric synthesis of CMI-977 (LDP-977): a potent anti-asthmatic drug lead. <i>Tetrahedron: Asymmetry</i> , 2003, 14, 1363-1370.	1.8	29
6	Synthesis of CMI-977, a Potent 5-Lipoxygenase Inhibitor. <i>Organic Process Research and Development</i> , 1999, 3, 73-76.	2.7	25
7	Practical syntheses of 4-fluoroprolines. <i>Journal of Fluorine Chemistry</i> , 2008, 129, 781-784.	1.7	25
8	Synthesis of novel C <sub>2</sub> -symmetric and pseudo C <sub>2</sub> -symmetric based diols, epoxides and dideoxy derivatives of HIV protease inhibitors. <i>Tetrahedron</i> , 1997, 53, 4769-4778.	1.9	22
9	Synthesis of a novel C <sub>2</sub> -symmetrical (2S,5S)-2,5-bis-[(1,1-dimethylethoxy)carbonylamino]-1,6-diphenylhex-3-ene: Applications in the synthesis of potential HIV protease inhibitors. <i>Tetrahedron Letters</i> , 1995, 36, 2505-2508.	1.4	20
10	A Practical Synthesis of (R)-( $\hat{1}$ )-Phenylephrine Hydrochloride. <i>Organic Process Research and Development</i> , 1998, 2, 422-424.	2.7	20
11	A Versatile Approach to Anti-Asthmatic Compound CMI-977 and its Six-Membered Analogue. <i>Synthesis</i> , 2000, 2000, 557-560.	2.3	17
12	Kinetic Resolution of Aryl Glycidyl Ethers: A Practical Synthesis of Optically Pure $\beta$ -Blocker $\hat{1}$ -S-Metoprolol. <i>Heterocycles</i> , 1998, 48, 1471.	0.7	15
13	General strategy for a short and efficient synthesis of 3-hydroxy-4-methylprolines (HMP). <i>Tetrahedron Letters</i> , 2006, 47, 9215-9219.	1.4	11
14	A Short and Efficient Stereoselective Synthesis of the Potent 5-Lipoxygenase Inhibitor CMI-977. <i>Synthetic Communications</i> , 2000, 30, 1955-1961.	2.1	10
15	Reverse Pharmacology. , 2017, , 89-126.		10
16	Novel macrolides via meso-tetraarylmetalloporphyrin assisted oxidations. <i>Tetrahedron Letters</i> , 1996, 37, 787-790.	1.4	9
17	Stereoselective syntheses of pharmaceutically relevant chiral tetrahydrofurans from (S)- and (R)-glyceraldehyde derivatives. <i>Tetrahedron: Asymmetry</i> , 2005, 16, 1113-1123.	1.8	7
18	Stereoselective synthesis of (2R,3S,4S,5R)-trans-3,4-dihydroxy-5-(4-fluorophenoxymethyl)-2-(1-N-hydroxyureidyl-3-butyn-4-yl)tetrahydrofuran and (2R,3S,4S,5R)-trans-5-ethynyl-2-(4-fluorophenoxymethyl)-3,4-O-isopropylidene tetrahydrofuran from mannose diacetonide. <i>Tetrahedron: Asymmetry</i> , 2005, 16, 1135-1140.	1.8	7

#	ARTICLE	IF	CITATIONS
19	Stereoselective synthesis of (2S,7S)-7-(4-phenoxyethyl)-2-(1-N-hydroxyureidyl-3-butyn-4-yl)oxepane: a potential anti-asthmatic drug candidate. <i>Tetrahedron: Asymmetry</i> , 2005, 16, 935-939.	1.8	6
20	Chemical modification of erythromycin: Novel reaction observed by treatment with metalloporphyrins. <i>Tetrahedron Letters</i> , 1994, 35, 3837-3840.	1.4	4
21	Stereoselective synthesis of chiral tetrahydrofurans with potent 5-LO inhibitory activity. <i>Tetrahedron: Asymmetry</i> , 2005, 16, 1125-1133.	1.8	4
22	A Novel and Simple Asymmetric Synthesis of CMI-977 (LDP-977): A Potent anti-Asthmatic Drug Lead.. <i>ChemInform</i> , 2003, 34, no.	0.0	0
23	Building Research Businesses on Integration of Basic and Applied Research: Value Creation and New Opportunities for the Chemical Enterprise. <i>ACS Symposium Series</i> , 2014, , 191-197.	0.5	0